ENDRA Life Sciences to Host Third Quarter 2020 Financial Results Conference Call and Webcast on Monday, November 16, 2020 at 4:30 p.m. ET
ANN ARBOR, MI / ACCESSWIRE / November 5, 2020 / ENDRA Life Sciences Inc. ("ENDRA") (NASDAQ:NDRA), a pioneer of Thermo Acoustic Enhanced UltraSound (TAEUS™), today announced that its third quarter financial results will be released on Monday, November 16, 2020 after the U.S. financial markets close. Management will host a conference call and webcast at 4:30 p.m. ET to discuss the results and provide an update on recent corporate developments.
U.S./Canada Dial-in Number: 844-369-8774
International Dial-in Number: 862-298-0844
Replay Dial-in Number: 877-481-4010
Replay International Dial-in Number: 919-882-2331
Replay Passcode: 38486
A telephone replay will be available November 16, 2020 through 4:30 p.m. ET on November 23, 2020.
A live audio webcast will be available through the Events and Presentations page of the Investors section of the company's website at www.endrainc.com. A replay of the webcast will be available on the website for 90 days.
About ENDRA Life Sciences Inc.
ENDRA Life Sciences is the pioneer of Thermo Acoustic Enhanced UltraSound (TAEUS™), a ground-breaking technology being developed to visualize tissue like CT or MRI, but at 1/50th the cost and at the point of patient care. TAEUS is designed to work in concert with the over one million ultrasound systems in use globally today. TAEUS is initially focused on the measurement of fat in the liver as a means to assess and monitor Non-Alcoholic Fatty Liver Disease (NAFLD) and inflammation (NASH), chronic liver conditions that affect over one billion people globally, and for which there are no practical diagnostic tools. Beyond the liver, ENDRA is exploring several other clinical applications of TAEUS, including visualization of tissue temperature during energy-based surgical procedures. For more information, please visit www.endrainc.com.
Investor Relations Contact:
Kim Sutton Golodetz
LHA Investor Relations
SOURCE: ENDRA Life Sciences Inc.
View source version on accesswire.com: